Fluticasone furoate
| Clinical data | |
|---|---|
| Trade names | Flonase, Sensimist, Veramyst, Avamys, Ellipta, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intranasal, by mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 0.51% (Intranasal) |
| Protein binding | 91% |
| Metabolism | Intranasal Liver (CYP3A4-mediated) |
| Elimination half-life | 15 hours |
| Excretion | Kidney |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.158.130 |
| Chemical and physical data | |
| Formula | C27H29F3O6S |
| Molar mass | 538.58 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Fluticasone furoate, sold under the brand name Flonase Sensimist among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.[9] It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol.[10] Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.[6][11]
It was approved for medical use in the United States in April 2007, and in the European Union in November 2008.[12][8] In 2021, fluticasone was the 23rd most commonly prescribed medication in the United States, with more than 25 million prescriptions.[13][14]
- ^ "Fluticasone Use During Pregnancy". Drugs.com. 9 January 2019. Archived from the original on 26 March 2019. Retrieved 4 February 2020.
- ^ "AVAMYS fluticasone furoate nasal spray bottle (131443)". Department of Health and Ages Care. 27 May 2022. Archived from the original on 2 March 2023. Retrieved 1 April 2023.
- ^ "Arnuity Elliptafluticasone furoate 50 microgram powder for inhalation dry powder inhaler (300141)". Department of Health and Ages Care. 26 May 2022. Archived from the original on 2 March 2023. Retrieved 1 April 2023.
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
- ^ "Avamys 27.5 micrograms/spray, nasal spray suspension - Summary of Product Characteristics (SmPC)". (emc). 4 June 2021. Archived from the original on 8 June 2023. Retrieved 18 June 2023.
- ^ a b Cite error: The named reference
Flonase Sensimist FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Arnuity Ellipta FDA labelwas invoked but never defined (see the help page). - ^ a b "Avamys EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 June 2020. Retrieved 5 June 2020.
- ^ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–362. doi:10.1159/000216193. PMID 19571596.
- ^ Kaliner MA (2011). Rhinitis, An Issue of Immunology and Allergy Clinics. Elsevier Health Sciences. p. 548. ISBN 978-1-4557-0932-8.
- ^ "Veramyst- fluticasone furoate spray, metered". DailyMed. 1 March 2010. Archived from the original on 5 February 2020. Retrieved 4 February 2020.
- ^ "Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051". U.S. Food and Drug Administration (FDA). 30 August 2010. Archived from the original on 5 February 2020. Retrieved 4 February 2020.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Fluticasone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.